Tumani Hayrettin
Dept. of Neurology, University of Ulm, Oberer Eselsberg 45, 89081, Ulm, Germany.
J Neurol. 2006 Sep;253 Suppl 5:V66-9. doi: 10.1007/s00415-006-5011-1.
IVIG treatment has been tried in several neurological diseases with presumed immunopathogenesis. Many of the rare neurological diseases seem to benefit from IVIG treatment; however, negative results have been rarely published. Despite the majority of positive results, a general use of IVIG cannot be recommended for these diseases. Beside the lack of controlled studies and the small numbers of reported cases, a publication bias has to be considered since negative study results are usually not reported. Therefore, at this stage treatment with IVIG should be used in conjunction with controlled therapy trials.
静脉注射免疫球蛋白（IVIG）治疗已在几种推测有免疫发病机制的神经疾病中进行了尝试。许多罕见的神经疾病似乎都能从IVIG治疗中获益；然而，很少有阴性结果被发表。尽管大多数结果是阳性的，但对于这些疾病，仍不建议普遍使用IVIG。除了缺乏对照研究和报告病例数量较少外，还必须考虑发表偏倚，因为阴性研究结果通常不会被报告。因此，在现阶段，IVIG治疗应与对照治疗试验相结合使用。
